Flamel Technologies S.A. (ADR)  

(Public, NASDAQ:FLML)   Watch this stock  
Find more results for flml
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 9.30 - 19.50
Open     -
Vol / Avg. 0.00/374,907.00
Mkt cap 713.28M
P/E     -
Div/yield     -
EPS -2.32
Shares 40.19M
Beta 0.92
Inst. own 73%
Jul 27, 2015
Half Year 2015 Flamel Technologies SA Earnings Release (Estimated) Add to calendar
Jun 24, 2015
Flamel Technologies SA Annual Shareholders Meeting (Estimated) - 5:30AM EDT - Add to calendar
Jun 1, 2015
Flamel Technologies SA at Jefferies Global Healthcare Conference - 4:30PM EDT - Add to calendar
May 15, 2015
Q1 2015 Flamel Technologies SA Earnings Call
May 15, 2015
Q1 2015 Flamel Technologies SA Earnings Release
Mar 19, 2015
Full Year 2014 Flamel Technologies SA Earnings Call
Mar 19, 2015
Full Year 2014 Flamel Technologies SA Earnings Release
Mar 12, 2015
Flamel Technologies SA at Barclays Healthcare Conference
Mar 10, 2015
Flamel Technologies SA at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -1074.98% -601.85%
Operating margin -1129.10% -635.24%
EBITD margin - -50.51%
Return on average assets - -61.23%
Return on average equity - -1156.13%
Employees 246 -
CDP Score - -


33, avenue du Dr. Georges Levy, Venissieux Cedex, PARC CLUB DU MOULIN A VENT
+33-4-72783434 (Phone)
+33-4-72783435 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Flamel Technologies SA is a pharmaceutical company. The Company’s focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Company’s products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR, the lead product using the Company’s Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate), a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.

Officers and directors

Stephen H. Willard Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Michael S. Anderson Chief Executive Officer, Director
Bio & Compensation  - Reuters
Sian Crouzet Principal Financial Officer
Bio & Compensation  - Reuters
Rafael Jorda Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Steven A. Lisi Senior Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregg Stetsko Ph.D. Vice President - Research & Development
Bio & Compensation  - Reuters
Catherine Castan Director - Micropump Platform (Oral Drugs) and Intellectual Property
Bio & Compensation  - Reuters
Christian Kalita Pharmacist and Director - Quality Assurance and Regulatory Affairs
Bio & Compensation  - Reuters
Elie Vannier Director
Age: 64
Bio & Compensation  - Reuters
Catherine Brechignac PH.D Independent Director
Bio & Compensation  - Reuters